NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that revenues for the third quarter rose 3 percent year over year as it narrowly beat the consensus Wall Street estimates on the top and bottom lines.

The company took in $3.19 billion in total revenues for the three months ended Sept. 28, up from $3.09 billion a year ago, and edging out the average analyst estimate of $3.18 billion. Organically, revenues grew 2 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.